Researchers at Johns Hopkins University report that two areas of the brain, the entorhinal cortex and the amygdala, show signs of Alzheimer's disease before the changes reach the hippocampus, the region doctors usually examine for evidence of the disease. The team analyzed hundreds of brain scans from people at different stages of Alzheimer's and found that both regions began to shrink earlier than the hippocampus. The work was published in NeuroImage Reports and was being presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience.
The study drew on MRI and PET scans from two independent cohorts, the Alzheimer's Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study. The scans covered people who were symptom-free, people with cognitive impairment, and people who died from the disease. Across both groups, the entorhinal cortex and amygdala showed greater relative atrophy and volume loss compared with the hippocampus during the early phase of the disease. The entorhinal cortex is involved in retrieving old memories, and the amygdala is linked to emotional memory.
The researchers also found that the gray matter shrinkage was spatially linked to changes in tau protein, a known hallmark of Alzheimer's, as measured by PET imaging and digital pathology. Lead researchers said measuring atrophy in these two regions together could serve as a better early predictor and a promising new biomarker, particularly as brain scanning becomes more available and affordable. Co-author Marilyn Albert, director of the Johns Hopkins Alzheimer's Disease Research Center, said the goal is to treat people before symptoms develop so the disease may be delayed or even stopped.
The timing is the central point. Co-author Meaghan Morris, a neuropathologist, noted that as biomarkers and treatments become more available, knowing who is likely to develop cognitive decline will matter a great deal for risk stratification. The article notes that doctors might eventually begin scanning these regions in people with a family history of Alzheimer's or other concerns, starting in their 30s and 40s, though that remains a possibility the researchers raised rather than an established practice.
The next step, according to the team, is to examine the molecular changes in these regions and how they relate to tau protein. The researchers said that understanding those molecular neighborhoods could support the development of therapies.